Dendreon, the Washington state-based manufacturer of the prostate cancer immunotherapy vaccine sipuleucel-T, known as Provenge, has applied to the FDA to quadruple its New Jersey factory where Provenge is made.
Even if it receives FDA approval, Dendreon claims it will have to establish two additional factories in Georgia and California just to keep up with demand.
Dendreon has found itself under heightened scrutiny from the FDA and the Centers for Medicare and Medicaid Services, since Provenge was estimated to cost about $93,000, while extending life for patients by only four months.
CANCER TYPE(S)
Prostate cancer
TREATMENT TYPE(S)
Therapeutic vaccine
Source
Washington Post
Seattle pi
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
